Board Committee Changes

27 April 2023 07:05 BST

AstraZeneca Board Committee Changes

AstraZeneca PLC (the Company) announced today a number of Board Committee changes:

>    Michel Demaré will succeed Leif Johansson as Chair of the Nomination and Governance Committee, with effect from the conclusion of the Company's Annual General Meeting today, 27 April 2023.

>    Nazneen Rahman will become a member of the Remuneration Committee, effective 1 May 2023.

>    Euan Ashley will succeed Nazneen Rahman as Chair of the Science Committee, effective 1 June 2023.  Dr Rahman will remain as a member of the Science Committee.

>    Euan Ashley will become a member of the Nomination and Governance Committee, effective 1 June 2023.

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

Contacts

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

Adrian Kemp
Company Secretary

AstraZeneca PLC